{
  "docId": "019de071-a0aa-74fc-b780-f72cc7f02158",
  "docSlug": "6af314fff9e6eaaf966098f4c73a6229",
  "documentTitle": "Mink Therapeutics | IPO Presentation Deck | 36 slides",
  "authorId": "mink-therapeutics",
  "authorName": "MiNK Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7860465,
  "pageNumber": 3,
  "pageCount": 36,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 6,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/3",
  "deckHref": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158",
  "deckJsonHref": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json",
  "deckAnchorHref": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.7,
        "x": 0.25,
        "y": 0.45
      },
      "kind": "list",
      "text": "Fund the planned early development of our monotherapy and combination study of AGENT-797; Fund the development of AGENT-797 through completion of our Phase 1 clinical trial; Fund IND-enabling studies; Fund our process validation; Working capital",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ba0fc2b-b60f-40c9-85d0-51bcf1de5404",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "table",
      "text": "Issuer: MiNK Therapeutics, Inc.; Ticker / Exchange: INKT / Nasdaq Global Market; Base Offering Shares: 4,000,000; Price Range: $12.00 - $14.00; Gross Proceeds: $52.0 million; Option to Purchase Shares: 600,000; Lock-Up Period: 180 days",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "690d7b5f-5a8c-4b93-93d7-d148fa5f5b68",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.35,
        "y": 0.05
      },
      "kind": "title",
      "text": "Offering Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5cfbefc-f95d-4493-a228-21e125c477f9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "e1f77821-b1c4-4d0b-9c95-025d1aa31fd1",
      "evidence": "table/data: Issuer: MiNK Therapeutics, Inc.; Ticker / Exchange: INKT / Nasdaq Global Market; Base Offering Shares: 4,000,000; Price Range: $12.00 - $14.00; Gross Proceeds: $52.0 million; Option to Purchase Shares: 600,00",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}